Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Operating Expenses (2016 - 2025)

Vanda Pharmaceuticals' Operating Expenses history spans 16 years, with the latest figure at $97.6 million for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 53.74% to $97.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $367.3 million, a 53.39% increase, with the full-year FY2025 number at $367.3 million, up 53.39% from a year prior.
  • Operating Expenses hit $97.6 million in Q4 2025 for Vanda Pharmaceuticals, up from $87.5 million in the prior quarter.
  • Over the last five years, Operating Expenses for VNDA hit a ceiling of $97.6 million in Q4 2025 and a floor of $44.8 million in Q3 2023.
  • Historically, Operating Expenses has averaged $64.4 million across 5 years, with a median of $59.9 million in 2021.
  • Biggest five-year swings in Operating Expenses: decreased 27.03% in 2023 and later soared 60.62% in 2025.
  • Tracing VNDA's Operating Expenses over 5 years: stood at $59.4 million in 2021, then decreased by 2.58% to $57.9 million in 2022, then fell by 9.49% to $52.4 million in 2023, then grew by 21.2% to $63.5 million in 2024, then soared by 53.74% to $97.6 million in 2025.
  • Business Quant data shows Operating Expenses for VNDA at $97.6 million in Q4 2025, $87.5 million in Q3 2025, and $91.1 million in Q2 2025.